Navigation Links
Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
Date:12/24/2013

diflunisal is inexpensive and readily available.

To date, no other drug treatment has achieved this level of benefit for this rare disorder.

"Our results show that diflunisal represents an alternative to liver transplantation, the current standard of care for this devastating disease," said Berk. "We hope that this study prompts the identification of other widely-used generic drugs for treatment of rare diseases."

"We are pleased and optimistic about the results of this study, and are encouraged about the potential for repurposing of generic medication to bring treatments to rare and more common diseases," said Robin Conwit, MD, a Program Director with the National Institute of Neurological Disorders and Stroke (NINDS).


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Oxygen levels increase and decrease the effectiveness of anti-inflammatory therapies
2. Researchers say tart cherries have the highest anti-inflammatory content of any food
3. Study shows Where Alzheimers starts and how it spreads
4. Wayne State cholesterol study shows algal extracts may counter effects of high fat diets
5. Telecoupling science shows Chinas forest sustainability packs global impact
6. H. pylori vaccine shows promise in mouse studies
7. Deepwater Horizon NRDA study shows possible oil impact on dolphins
8. Research shows how household dogs protect against asthma and infection
9. Harvard study shows sprawl threatens water quality, climate protection, and land conservation gains
10. Study shows first link between altitude and concussion
11. International gene therapy trial for bubble boy disease shows promising early results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... The microscopic phytoplankton Aureococcus anophagefferens , which causes ... to be a fierce competitor. In the first ... found that Aureococcus , unique gene complement allows ... human-modified ecosystems, which could help explain the global increases ...
... pathways that are mutated in many forms of cancer, ... disease including hypertrophic cardiomyopathy (HCM), a thickening of ... sudden death in children and young adults , have ... in the lab. In two separate but ...
... group of chemical compounds used by a species of ... promising antimalarial properties for humans. The compounds are part ... to battle enemies and that may provide a ... novel analytical process, researchers at the Georgia Institute of ...
Cached Biology News:First harmful algal bloom species genome sequenced 2First harmful algal bloom species genome sequenced 3Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... , NATICK, Mass., Sept. 14 Boston ... that it has entered into a co-marketing agreement with ... testing solutions for urinary incontinence. Bladder Health Network ... supplies and results analysis, helping to ensure that physicians ...
... 14 Health Robotics today reported,that Dr M Group has ... of its I.V. Compounding Centers in Malaysia,Singapore, Indonesia, Vietnam, and ... on 2 companies in the field of I.V.,Robotics, the doubts ... announced multi-year delays in bringing their robot to first,hospital,s use], ...
... , , , ... announced that the results of a comprehensive review of safety data from ... Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, ... risk-benefit profile of pirfenidone in IPF patients, a comprehensive review of safety ...
Cached Biology Technology:Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 2Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 2Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 3Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 5Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 6Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 7Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 8
pH-insensitive fluorescence (pH 2-12)...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Biology Products: